National Institute on Drug Abuse; Notice of Closed Meetings, 68939 [2019-27102]
Download as PDF
<![CDATA[
Federal Register / Vol. 84, No. 242 / Tuesday, December 17, 2019 / Notices
Number of
respondents
Data collection instrument(s)
Responses
per
respondent
Total annual
response
Request for Approval of Deferment (IHS–856–11) .....
Preferred Placement (IHS–856–12) ............................
Notice of Impending Graduation (IHS–856–13) ..........
Notification of Deferment Program (IHS–856–14) ......
Placement Update (IHS–856–15) ...............................
Annual Status Report (IHS–856–16) ...........................
Lost Stipend Payment (IHS–856–19) ..........................
Summer School Request (IHS–856–21) .....................
Change of Name or Address (IHS–856–22) ...............
Request for Credit Validation (IHS–856–23) ...............
Scholarship Program Agreement (IHS–817) ...............
Health Professions Contract (IHS–818) ......................
60
150
170
60
170
200
10
100
20
30
60
225
1
1
1
1
1
1
1
1
1
1
1
1
60
150
170
60
170
200
10
100
20
30
60
225
Total ......................................................................
........................
........................
3,275
Burden hour
per response *
0.13
0.50
0.17
0.13
0.18
0.25
0.13
0.10
0.13
0.10
0.16
0.16
68939
Annual
burden hours
(8 min) ...........
(30 min) .........
(10 min) .........
(8 min) ...........
(11 min) .........
(15 min) .........
(8 min) ...........
(6 min) ...........
(8 min) ...........
(6 min) ...........
(10 min) .........
(10 min) .........
8
75
28
8
31
50
2
10
3
3
10
38
................................
1,283
* For ease of understanding, burden hours are also provided in actual minutes.
There are no direct costs to
respondents other than their time to
voluntarily complete the forms and
submit them for consideration. The
estimated cost for the federal
government is $145,223.00 (contractor)
to work on the program with IHS
program staff.
Requests for Comments: Your written
comments and/or suggestions are
invited on one or more of the following
points:
(a) Whether the information collection
activity is necessary to carry out an
agency function;
(b) whether the agency processes the
information collected in a useful and
timely fashion;
(c) the accuracy of the public burden
estimate (the estimated amount of time
needed for individual respondents to
provide the requested information);
(d) whether the methodology and
assumptions used to determine the
estimates are logical;
(e) ways to enhance the quality,
utility, and clarity of the information
being collected; and
(f) ways to minimize the public
burden through the use of automated,
electronic, mechanical, or other
technological collection techniques or
other forms of information technology.
Chris Buchanan,
Assistant Surgeon General, USPHS, Deputy
Director, Indian Health Service.
[FR Doc. 2019–27121 Filed 12–16–19; 8:45 am]
BILLING CODE 4165–16–P
jbell on DSKJLSW7X2PROD with NOTICES
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute on Drug Abuse;
Notice of Closed Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
VerDate Sep<11>2014
18:15 Dec 16, 2019
Jkt 250001
amended, notice is hereby given of the
following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute on
Drug Abuse Special Emphasis Panel; PHASE
I: NIDA Avant-Garde Award Program for
HIV/AIDS and Drug Use Research (DP1)
(Mail) and Phase II: NIDA Avant Garde
Award Program for HIV/AIDs and Drug Use
Research (DP1) (Interview).
Date: December 18, 2019.
Time: 8:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Courtyard by Marriott, 5520
Wisconsin Avenue, Chevy Chase, MD 20815.
Contact Person: Hiromi Ono, Ph.D.,
Scientific Review Officer, Office of
Extramural Affairs, National Institute on
Drug Abuse, National Institutes of Health,
DHHS, 6001 Executive Boulevard, Room
4238, MSC 9550, Bethesda, MD 20892, 301–
402–6020, hiromi.ono@nih.gov.
This notice is being published less than 15
days prior to the meeting due to the urgent
need to meet timing limitations imposed by
the intramural research review cycle.
Name of Committee: National Institute on
Drug Abuse Special Emphasis Panel;
Mechanism for Time-Sensitive Drug Abuse
Research (R21 Clinical Trial Optional).
Date: December 20, 2019.
Time: 1:00 p.m. to 3:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Neuroscience Center Building (NSC), 6001
Executive Boulevard, Rockville, MD 20852
(Telephone Conference Call).
PO 00000
Frm 00065
Fmt 4703
Sfmt 4703
Contact Person: Susan O. McGuire, Ph.D.,
Scientific Review Officer, Office of
Extramural Affairs, National Institute on
Drug Abuse, National Institutes of Health,
DHHS, 6001 Executive Blvd., Room 4245,
Rockville, MD 20852, 301–435–1426,
mcguireso@mail.nih.gov.
This notice is being published less than 15
days prior to the meeting due to the timing
limitations imposed by the review and
funding cycle.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.279, Drug Abuse and
Addiction Research Programs, National
Institutes of Health, HHS)
Dated: December 11, 2019.
Tyeshia M. Roberson,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2019–27102 Filed 12–16–19; 8:45 am]
BILLING CODE 4140–01–P
INSTITUTE OF AMERICAN INDIAN AND
ALASKA NATIVE CULTURE AND ARTS
DEVELOPMENT
Request for Nominations to the Board
of Trustees
Institute of American Indian
and Alaska Native Culture and Arts
Development (aka Institute of American
Indian Arts).
ACTION: Notice; request for nominations.
AGENCY:
The Board directs the
Administration of the Institute of
American Indian and Alaska Native
Culture and Arts Development,
including soliciting, accepting, and
disposing of gifts, bequests, and other
properties for the benefit of the Institute.
The Institute provides scholarly study of
and instruction in Indian art and
culture, and establishes programs which
culminate in the awarding of degrees in
the various fields of Indian art and
culture. The Board consists of thirteen
members appointed by the President of
SUMMARY:
E:\FR\FM\17DEN1.SGM
17DEN1
]]>Agencies
[Federal Register Volume 84, Number 242 (Tuesday, December 17, 2019)]
[Notices]
[Page 68939]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2019-27102]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Institute on Drug Abuse; Notice of Closed Meetings
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended, notice is hereby given of the following meetings.
The meetings will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended. The grant applications and the discussions could
disclose confidential trade secrets or commercial property such as
patentable material, and personal information concerning individuals
associated with the grant applications, the disclosure of which would
constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: National Institute on Drug Abuse Special
Emphasis Panel; PHASE I: NIDA Avant-Garde Award Program for HIV/AIDS
and Drug Use Research (DP1) (Mail) and Phase II: NIDA Avant Garde
Award Program for HIV/AIDs and Drug Use Research (DP1) (Interview).
Date: December 18, 2019.
Time: 8:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant applications.
Place: Courtyard by Marriott, 5520 Wisconsin Avenue, Chevy
Chase, MD 20815.
Contact Person: Hiromi Ono, Ph.D., Scientific Review Officer,
Office of Extramural Affairs, National Institute on Drug Abuse,
National Institutes of Health, DHHS, 6001 Executive Boulevard, Room
4238, MSC 9550, Bethesda, MD 20892, 301-402-6020,
[email protected].
This notice is being published less than 15 days prior to the
meeting due to the urgent need to meet timing limitations imposed by
the intramural research review cycle.
Name of Committee: National Institute on Drug Abuse Special
Emphasis Panel; Mechanism for Time-Sensitive Drug Abuse Research
(R21 Clinical Trial Optional).
Date: December 20, 2019.
Time: 1:00 p.m. to 3:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, Neuroscience Center
Building (NSC), 6001 Executive Boulevard, Rockville, MD 20852
(Telephone Conference Call).
Contact Person: Susan O. McGuire, Ph.D., Scientific Review
Officer, Office of Extramural Affairs, National Institute on Drug
Abuse, National Institutes of Health, DHHS, 6001 Executive Blvd.,
Room 4245, Rockville, MD 20852, 301-435-1426,
[email protected].
This notice is being published less than 15 days prior to the
meeting due to the timing limitations imposed by the review and
funding cycle.
(Catalogue of Federal Domestic Assistance Program Nos. 93.279, Drug
Abuse and Addiction Research Programs, National Institutes of
Health, HHS)
Dated: December 11, 2019.
Tyeshia M. Roberson,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2019-27102 Filed 12-16-19; 8:45 am]
BILLING CODE 4140-01-P
